Tokio Marine Asset Management CO LTD Innoviva, Inc. Transaction History

Tokio Marine Asset Management CO LTD

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 02, 2023	BUY	$12.37 - $13.89 $14,843 - $16,668	1,200 Added 11.11%	12,000 $155,000
Q1 2023 May 11, 2023	BUY	$10.73 - $13.6 $115,884 - $146,880	10,800 New	10,800 $121,000
Q2 2022 Aug 09, 2022	BUY	$14.32 - $19.88 $18,616 - $25,844	1,300 Added 10.57%	13,600 $201,000
Q1 2022 May 13, 2022	SELL	$15.39 - $20.25 $35,397 - $46,575	-2,300 Reduced 15.75%	12,300 $238,000
Q4 2021 Jan 26, 2022	SELL	$15.91 - $18.72 $101,824 - $119,808	-6,400 Reduced 30.48%	14,600 $252,000
Q3 2021 Nov 15, 2021	SELL	$13.06 - $17.24 $22,202 - $29,307	-1,700 Reduced 7.49%	21,000 $351,000
Q2 2021 Aug 12, 2021	SELL	$11.45 - $13.96 $28,625 - $34,900	-2,500 Reduced 9.92%	22,700 $304,000
Q1 2021 May 17, 2021	SELL	$11.06 - $12.87 $56,406 - $65,637	-5,100 Reduced 16.83%	25,200 $301,000
Q4 2020 Feb 16, 2021	BUY	$9.33 - $12.48 $20,526 - $27,456	2,200 Added 7.83%	30,300 $375,000
Q3 2020 Nov 09, 2020	BUY	$10.33 - $14.49 $28,924 - $40,572	2,800 Added 11.07%	28,100 $294,000
Q2 2020 Aug 07, 2020	SELL	$11.49 - $15.26 $26,427 - $35,098	-2,300 Reduced 8.33%	25,300 $354,000
Q1 2020 May 12, 2020	BUY	$8.11 - $15.23 $2,433 - $4,569	300 Added 1.1%	27,600 $325,000
Q4 2019 Feb 14, 2020	SELL	$10.28 - $14.38 $44,204 - $61,834	-4,300 Reduced 13.61%	27,300 $387,000
Q3 2019 Oct 29, 2019	BUY	$10.05 - $14.55 $22,110 - $32,010	2,200 Added 7.48%	31,600 $333,000
Q2 2019 Jul 25, 2019	BUY	$13.1 - $14.95 $19,650 - $22,425	1,500 Added 5.38%	29,400 $428,000
Q1 2019 Apr 25, 2019	BUY	$13.69 - $20.06 $381,951 - $559,674	27,900 New	27,900 $391,000

229

79.2M

37.6K

300

Ticker INVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 69,706,000
Market Cap $1.33B
Description
Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a ...

Get notified when there are updates to the investment portfolio of Tokio Marine Asset Management CO LTD, based on Form 13F filings with the SEC.

Stay updated on Tokio Marine Asset Management CO LTD with notifications on news.